Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study

Expert Opinion on Drug Delivery

Volumn 8, Issue 12, 2011, Pages 1543-1553

  Wray, Sibyl ^a   Armstrong, Robert ^a   Herrman, Craig ^a   Calkwood, Jonathan ^b   Cascione, Mark ^c   Watsky, Eric ^d   Hayward, Brooke ^e   Mercer, Brian ^e   Dangond, Fernando ^e  

^a Department of Hope Neurology ^*  (United States)

^b Minneapolis Clinic of Neurology   (United States)

^c Pfizer Inc   (United States)

^d PFIZER INC   (United States)

^e EMD SERONO INC   (United States)

Author keywords

Medication adherence; Multiple sclerosis; Subcutaneous injections

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; ATTENTION DISTURBANCE; AUTOINJECTOR; COGNITION; COGNITIVE DEFECT; COORDINATION DISORDER; CRANIAL NEUROPATHY; DEVICE SAFETY; DISEASE SEVERITY; DRUG EFFICACY; EXECUTIVE FUNCTION; FEMALE; GAIT DISORDER; HEADACHE; HEMATOMA; HUMAN; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL APPARATUS, EQUIPMENT AND SUPPLIES; MEMORY DISORDER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE FATIGUE; NEUROLOGIC EXAMINATION; OPEN STUDY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE; REFLEX DISORDER; RELIABILITY; RISK ASSESSMENT; SELF INJECTION; SENSORY DYSFUNCTION; SHORT FORM 36; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SATISFACTION; QUESTIONNAIRES; SELF ADMINISTRATION; YOUNG ADULT;

EID: 81855209826     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.628656     Document Type: Article

References (14)

1. WHO. Adherence to long-term therapies: evidence for action. Available from: http:// www.who.int/chp/knowledge/ publications/adherence-report/en/index. html [Accessed 17 December 2010]
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97 (Pubitemid 41127293)
3. Markowitz CE. The current landscape and unmet needs in multiple sclerosis. Am J Manag Care 2010;16:S211-18
4. Lugaresi A, Durastanti V, Gasperini C, et al. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the Co Sa study. Clin Neuropharmacol 2008;31:167-72 (Pubitemid 351787112)
5. Phillips JT, Weinstock-Guttman B. Assessing patient satisfaction with autoinjector for IM IFNbeta-1a (Avonex). Int J MS Care 2007;9:72
6. Hyllested-Winge J, Jensen KH, Rex J. A review of 25 years' experience with the Novo Pen family of insulin pens in the management of diabetes mellitus. Clin Drug Investig 2010;30:643-74
7. Mc Donald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
8. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "Mc Donald Criteria". Ann Neurol 2005;58:840-6
9. Wilken JA, Kane R, Sullivan CL, et al. The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler 2003;9:119-27 (Pubitemid 36426985)
10. Benedict RH, Cookfair D, Gavett R et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006;12:549-58 (Pubitemid 44070305)
11. Krupp LB, La Rocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3 (Pubitemid 19246303)
12. Quality Metric, Inc. and Medical Outcomes Trust. SF-36v2 Health Survey. Available from: http://www.qualitymetric. com/What We Do/Generic Health Surveys/ SF36v2Health Survey/tabid/185/Default. aspx and http://www.dfwback.com/pdfs/ SF36Health Survey.pdf [Accessed 20 December 2010]
13. Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol 2010;10:28
14. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:585-91 (Pubitemid 41387705)